Content area
Full Text
Ethicon announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for EVARREST Fibrin Sealant Patch, which leverages biologics to rapidly and reliably stop problematic bleeding during surgery. The expanded indication supports the use of EVARREST as an adjunctive hemostat across a broad range of challenging patient types and surgical situations. This represents a significant milestone in controlling problematic bleeding situations with high confidence, while advancing patient care.
Problematic bleeding that is more than routine and resistant to conventional means of control is one of the most threatening complications of surgery and a frequent cause of negative patient outcomes, posing significant clinical and economic challenges. In patients treated with hemostatic agents for a variety of...